| Compounds | Topics | Title | Date |
|---|---|---|---|
| THC | gvhd in mice via model | Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model. | Sep 2011 |
| Impaired hematopoiesis seen during GVHD was rescued by treatment with THC. Our results demonstrate for the first time that targeting cannabinoid receptors may constitute a novel treatment modality against acute GVHD. | |||
| CBD | gvhd in humans via trial (n=48) | Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. | Oct 2015 |
|
Ingestion Method: 300mg/day The combination of CBD with standard GVHD prophylaxis is a safe and promising strategy to reduce the incidence of acute GVHD. A randomized double-blind controlled study is warranted. | |||
| THC | gvhd in mice via experiment | d9-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells. | Sep 2015 |
| THC treatment significantly reduced T cell proliferation and activation in draining LNs of the recipient mice and decreased early stage rejection-indicator cytokines, including IL-2 and IFN-g. THC treatment also increased the allogeneic skin graft survival. | |||
| O-1602 | gvhd in vitro | A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10 | May 2015 |
| These data support the potential of CB2-selective agonists as useful therapeutic agents to prolong graft survival in transplant patients, and strengthens their potential as a new class of immunosuppressive agents with broader applicability. | |||